Efficacy and safety of fixed-dose losartan/hydrochlorothiazide/amlodipine combination versus losartan/hydrochlorothiazide combination in Japanese patients with essential hypertension

Clinical and Experimental Hypertension

Volumn 37, Issue 3, 2015, Pages 260-266

  Rakugi, Hiromi ^a   Tsuchihashi, Takuya ^b   Shimada, Kazuyuki ^c   Numaguchi, Hirotaka ^d   Nishida, Chisato ^d   Yamaguchi, Hiroya ^d   Shirakawa, Masayoshi ^d   Azuma, Kyoichi ^d   Fujita, Kenji P ^e  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b STEEL MEMORIAL YAWATA HOSPITAL   (Japan)

^c Shin Oyama City Hospital   (Japan)

^d Merck Sharp Dohm Res Labs Japan   (Japan)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Amlodipine; Hydrochlorothiazide; Japanese; Losartan

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS HYDROCHLOROTHIAZIDE PLUS LOSARTAN; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; UNCLASSIFIED DRUG; ANTIHYPERTENSIVE AGENT; DRUG COMBINATION; HYDROCHLOROTHIAZIDE; LOSARTAN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; DEPRESSED BLOOD PRESSURE; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ECZEMA; EDEMA; ESSENTIAL HYPERTENSION; FAINTNESS; FEMALE; HUMAN; HYPERURICEMIA; HYPOTENSION; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; ORTHOSTATIC HYPOTENSION; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; DRUG COMBINATION; DRUG EFFECTS; DRUG MONITORING; HYPERTENSION; JAPAN; MIDDLE AGED; PATHOPHYSIOLOGY; PROCEDURES; TREATMENT OUTCOME;

AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DRUG COMBINATIONS; DRUG MONITORING; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; JAPAN; LOSARTAN; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84928034948     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.3109/10641963.2014.954712     Document Type: Article

References (20)

1. Fukui T, Rahman M, Hayashi K, et al. Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: rationale, design, and methods. Hypertens Res 2003;26:979-90.
2. Gradman AH, Basile JN, Carter BL, Bakris GL. Combination therapy in hypertension. J Am Soc Hypertens 2010;4:42-50.
3. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013;31:1281-357.
4. Shimamoto K, Ando K, Fujita T, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res 2014;37:253-87.
5. Hagendorff A, Freytag S, Muller A, Klebs S. Pill burden in hypertensive patients treated with single-pill combination therapy - an observational study. Adv Ther 2013;30:406-19.
6. Chowdhury EK, Owen A, Krum H, et al. Barriers to achieving blood pressure treatment targets in elderly hypertensive individuals. J Hum Hypertens 2013;27:545-51.
7. Ingersoll KS, Cohen J. The impact of medication regimen factors on adherence to chronic treatment: a review of literature. J Behav Med 2008;31:213-24.
8. Sakima A, Ohshiro K, Nakada S, et al. Switching therapy from variable-dose multiple pill to fixed-dose single-pill combinations of angiotensin II receptor blockers and thiazides for hypertension. Clin Exp Hypertens 2011;33:309-15.
9. Sherrill B, Halpern M, Khan S, et al. Single-pill vs free-equivalent combination therapies for hypertension: a meta-analysis of health care costs and adherence. J Clin Hypertens (Greenwich) 2011;13: 898-909.
10. Hosoya T, Kuriyama S, Ohno I, et al. Antihypertensive effect of a fixed-dose combination of losartan/hydrochlorothiazide in patients with uncontrolled hypertension: a multicenter study. Clin Exp Nephrol 2012;16:269-78.
11. Saruta T, Ogihara T, Matsuoka H, et al. Antihypertensive efficacy and safety of fixed-dose combination therapy with losartan plus hydrochlorothiazide in Japanese patients with essential hypertension. Hypertens Res 2007;30:729-39.
12. Liang K, Zeger S. Longitudinal data analysis of continuous and discrete responses for pre-post designs. Sankyâ. Indian J Stat 2000; 62:134-48.
13. Robins JM, Wang N. Inference for imputation estimators. Biometrika 2000;87:113-24.
14. Kenward MG, Roger JH. Small sample inference for fixed effects from restricted maximum likelihood. Biometrics 1997;53:983-97.
15. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med 1985;4:213-26.
16. Clopper C, Pearson E. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934;26:404-13.
17. Lu K, Mehrotra DV, Liu G. Sample size determination for constrained longitudinal data analysis. Stat Med 2009;28:679-99.
18. Oparil S, Melino M, Lee J, et al. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: the TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. Clin Ther 2010;32: 1252-69.
19. Calhoun DA, Lacourciere Y, Chiang YT, Glazer RD. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial. Hypertension 2009;54: 32-9.
20. Neutel JM, Smith DH. Hypertension management: rationale for triple therapy based on mechanisms of action. Cardiovasc Ther 2013;31:251-8.